Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 1/2013

01.01.2013 | Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus

verfasst von: Samar Singh, Jyoti Bhat, Ping H. Wang

Erschienen in: Current Cardiology Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Over the past several years, there have been a significant number of new agents developed for the treatment of type 2 diabetes. Our goal in this article is to review the cardiovascular effects (risks and benefits) of these oral and non-insulin injectable agents. We review six major categories of diabetic therapies: biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, GLP-1 agonists, and DPP-IV inhibitors. In order to achieve a personalized regimen that aims for optimal outcomes, we must take into consideration each drug’s side effects, patients’ cardiovascular risk factors, and their individual health profile.
Literatur
1.
2.
Hemmignsen B, Lund SS, Wetterslev J, Vaag A. Oral hypoglycemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol. 2009;161:1–9.CrossRef
3.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef
4.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
5.
• Messaoudi SE, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011;22:445–53. This is a recent review of myocardial ischemia-reperfusion injury and metformin in animal models. PubMedCrossRef
6.
Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non insulin-dependent diabetes mellitus. J Diabetes Complicat. 2008;12:110–9.CrossRef
7.
Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Int Med. 2008;168:2070–80.CrossRef
8.
•• Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–25. This is one of the few randomized controlled trials, as a follow up to the UKPDS, that showed an improvement in macrovascular outcomes when metformin was added to an insulin regimen. PubMedCrossRef
9.
Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–8.PubMedCrossRef
10.
Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892–9.PubMedCrossRef
11.
McAlister FA, Eurich DT, Majumdar SR, Johnson JA, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent Monotherapy. Eur J Heart Fail. 2008;10:703–8.PubMedCrossRef
12.
Eurich DT, McAlister FA, Balckburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Available at bmj.com. Accessed 2007.
13.
Sadikot S, Mogensen CE. Risk of coronary artery disease associated with initial sulfonylurea treatment of patients with type 2 diabetes: a matched case–control study. Diabetes Res Clin Pr. 2008;82:391–5.CrossRef
14.
Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. JACC. 1998;31:950–6.PubMedCrossRef
15.
Evans JMM, Ogston SA, Reimann F, et al. No differences in mortality between users on pancreatic-specific and non-pancreatic specific sulfonylureas: a cohort analysis. Diabetes Obes Metab. 2008;10:350–2.PubMedCrossRef
16.
Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimeperide monotherapy. Diabetes Care. 2010;33:1224–9.PubMedCrossRef
17.
Andersson C, Gislason GH, Jorgensen JH, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pr. 2011;94:119–25.CrossRef
18.
Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K + channel blocker. Circulation. 1994;90:700–5.PubMedCrossRef
19.
Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning: a double-blind placebo controlled evaluation of glimeperide and glibenclamide. Eur Heart J. 1999;20:439–46.PubMedCrossRef
20.
Zeller M, Danchin M, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993–5002.PubMedCrossRef
21.
UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 2008;352:853–7.
22.
Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care. 2007;30:389–94.PubMedCrossRef
23.
• Pantalone KM, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimeperide monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14:803–9. A recent large retrospective review that showed an increased mortality with 3 different sulfonylureas compared to metformin. PubMedCrossRef
24.
Evans JMM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930–6.PubMedCrossRef
25.
Vameq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999;354:141–8.CrossRef
26.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, and glyburide monotherapy. N Engl J Med. 2006;355:2427–43.PubMedCrossRef
27.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2006;29:1963–72.PubMedCrossRef
28.
Nesto RW, Bell D. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American heart association and American diabetes association. Circulation. 2003;108:2941–8.PubMedCrossRef
29.
Haffner SM. Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl. 1997;15:S25–30.PubMed
30.
Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens. 2006;8:19–28.CrossRef
31.
Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797–802.PubMedCrossRef
32.
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–54.PubMedCrossRef
33.
Robinson JG. Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res. Article ID. 2008;891425:1–13.
34.
Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366:1279–89.PubMedCrossRef
35.
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73.PubMedCrossRef
36.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRef
37.
38.
• Standl E, Schnell O, Alpha-glucosidase inhibitors. Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation. Diabetes Vasc Dis Res. 2012;0:1–7. A recent review of studies done on the cardiovascular effects of acarbose.
39.
Van de Laar FA, Lucassen PL, Akkerma RP, et al. Alpha-glycosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–63.PubMedCrossRef
40.
• Lin SD, Wang JS, Hsu SR, et al. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonyurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complicat. 2011;25:332–8. A randomized study that showed the addition of acarbose to metformin causes much lower glucose variability throughout the day compared to the addition of a sulfonylurea, glimeperide. PubMedCrossRef
41.
Suzuki Y, Sano M, Hayashida K, et al. Are the effects of a-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett. 2009;583:2157–215.PubMedCrossRef
42.
Kajiyama S, Hasegawa G, Asano M, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res. 2008;28:137–43.PubMedCrossRef
43.
Chiasson J, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.PubMedCrossRef
44.
Chiasson J, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.PubMedCrossRef
45.
Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073–8.PubMedCrossRef
46.
Hanefeld M, Cagatay M, Petrowitsch T. Acarbose reduces the risk of myocardial infarction in type 2 diabetics: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMedCrossRef
47.
Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest. 2002;22:695–701.CrossRef
48.
Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1345–50.PubMedCrossRef
49.
Schisano B, Tripathi G, McGee K, et al. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia. 2011;54:1219–26.PubMedCrossRef
50.
Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991;14:732–7.PubMedCrossRef
51.
Satoh N, Shimatsu A, Yamada K, et al. An a-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2006;55:786–7.PubMedCrossRef
52.
Yokoyama H, Kannno S, Ishimura I, et al. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism. 2007;56:1458–63.PubMedCrossRef
53.
Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470–512.PubMedCrossRef
54.
Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93:3703–16.PubMedCrossRef
55.
Ahren B, Landin-Olsson M, Jansson P, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–84.PubMedCrossRef
56.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.PubMedCrossRef
57.
•• Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85. Important article demonstrating how significantly different diabetes outcomes are in patients who undergo bariatric surgery versus medical treatment of diabetes. This could potentially change the stringent requirements patients have to meet in order to qualify for bariatric surgery. PubMedCrossRef
58.
Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759–63.PubMedCrossRef
59.
Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275–86.PubMed
60.
• Addison D, Aguilar D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr Atheroscler Rep. 2011;13:115–22. Review article describing benefits of incretin therapies in treatment of cardiovascular disease. PubMedCrossRef
61.
Forst T, Weber MM, Pfutzner A. Cardiovascular benefits of GLP-1 based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res. 2012;2012:1–9.
62.
Courreges JP, Vilsbollt T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetic Med. 2008;25:1129–31.PubMedCrossRef
63.
Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist Exenatide twice daily or other glucose-lowering therapies. A retrospective analysis of the LifeLink database. Diabetes Care. 2011;34:90–5.PubMedCrossRef
64.
Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16–27.PubMedCrossRef
65.
Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes. 2009;58:A639.
Metadaten
Titel
Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
verfasst von
Samar Singh
Jyoti Bhat
Ping H. Wang
Publikationsdatum
01.01.2013
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 1/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0327-1

Weitere Artikel der Ausgabe 1/2013

Current Cardiology Reports 1/2013 Zur Ausgabe

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Imaging of Inflammation and Calcification in Aortic Stenosis

New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)

Impediments to Adherence to Post Myocardial Infarction Medications

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Modeling of Fractional Flow Reserve Based on Coronary CT Angiography

New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)

Platelet Function Monitoring and Clopidogrel

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Transcatheter Aortic Valve Repair, Imaging, and Electronic Imaging Health Record

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Coronary Calcium: New Insights, Recent Data, and Clinical Role

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen